LCAT抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07416(LCAT Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Lecithin-cholesterol acyltransferase (LCAT) is a key enzyme in lipid metabolism, primarily synthesized in the liver and circulating in plasma. It catalyzes the esterification of free cholesterol on high-density lipoprotein (HDL), facilitating cholesterol transport to the liver for excretion (reverse cholesterol transport). LCAT dysfunction is linked to rare genetic disorders like Familial LCAT Deficiency (FLD) and Fish-Eye Disease (FED), characterized by corneal opacity, anemia, and abnormal lipoprotein profiles. Reduced LCAT activity is also implicated in cardiovascular diseases due to impaired HDL maturation.

LCAT antibodies are immunological tools developed to detect, quantify, or modulate LCAT protein expression and activity. They include monoclonal and polyclonal antibodies used in assays (e.g., ELISA, Western blot) to study LCAT’s role in lipid homeostasis, diagnose genetic deficiencies, or evaluate therapeutic interventions. Some antibodies inhibit LCAT enzymatically to model disease conditions, while others support drug development targeting HDL metabolism. Recent research explores LCAT-enhancing therapies to boost HDL function, with antibodies serving as critical reagents to monitor LCAT levels in preclinical studies. However, challenges remain in standardizing antibody specificity and understanding LCAT’s dual role in atherosclerosis, necessitating further investigation. These antibodies thus bridge basic research, clinical diagnostics, and therapeutic innovation in lipid-related pathologies.